Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1989;80:51-64

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasenfuss, G.
Right arrow Articles by Just, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasenfuss, G.
Right arrow Articles by Just, H.

Circulation, Vol 80, 51-64, Copyright © 1989 by American Heart Association


ARTICLES

Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone

G Hasenfuss, C Holubarsch, HW Heiss, T Meinertz, T Bonzel, U Wais, M Lehmann and H Just
Department of Internal Medicine, University of Freiburg, Medical School, FRG.

Cardiotonic agents influence myocardial energy consumption by vasodilation, which may reduce energy demand, and by inotropism, which may increase it. To distinguish between the two effects, myocardial oxygen consumption must be analyzed in relation to its hemodynamic determinants. The coupling of myocardial oxygen consumption with its determinants was investigated in 22 patients with idiopathic dilated cardiomyopathy (NYHA Class II and III). Predicted myocardial oxygen consumption by the pressure-work index, the Bretschneider index, and the pressure-volume area correlated moderately with measured myocardial oxygen consumption (r = 0.57, p less than 0.001; r = 0.52, p less than 0.005; and r = 0.63, p less than 0.001). Multiple regression analysis, including left ventricular peak systolic wall stress, systolic stress- time integral, pressure-volume work, maximum rate of left ventricular pressure rise, and mean velocity of circumferential fiber shortening indicated that systolic stress-time integral is the major determinant of myocardial oxygen consumption (r = 0.75, p less than 0.001) in these patients. Enoximone, a phosphodiesterase inhibitor, has an inotropic and a vasodilating effect. To investigate the inotropic portion of the energy cost of this phosphodiesterase inhibitor, the influence of enoximone on myocardial oxygen consumption and systolic stress-time integral was compared with the effects of nitroprusside, which is a vasodilator only. Nitroprusside (10 patients) and enoximone (12 patients) reduced left ventricular systolic stress-time integral from 109 +/- 22 to 71 +/- 21 (p less than 0.005) and from 104 +/- 23 to 42 +/- 10 (p less than 0.001) 10(3) dynes.sec/cm2, respectively. Myocardial oxygen consumption decreased from 159 +/- 44 to 112 +/- 23 (p less than 0.005) and from 134 +/- 28 to 109 +/- 21 (p less than 0.001) microliters/beat/100 g, respectively. In both groups, there was a significant correlation between the decrease in myocardial oxygen consumption and the decrease in systolic stress-time integral. The slopes of the respective linear regression lines were significantly different (1.27 for nitroprusside and 0.51 nl.cm2/100 g.dynes.sec for enoximone, p less than 0.05), indicating a smaller decrease of myocardial oxygen consumption for a given decrease of stress-time integral with enoximone. Applying the pressure-work index or the pressure-volume area instead of systolic stress-time integral yielded comparable results. Thus, vasodilation reduces myocardial oxygen consumption in proportion to the reduction of stress-time integral. With enoximone, the energy-saving effect of vasodilation is counteracted in part by the increased energy d


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. N. Mazzadi, X. Andre-Fouet, N. Costes, P. Croisille, D. Revel, and M. F. Janier
Mechanisms leading to reversible mechanical dysfunction in severe CAD: alternatives to myocardial stunning
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2570 - H2582.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Yuda, V. Khoury, and T. H. Marwick
Influence of wall stress and left ventricular geometry on the accuracy of dobutamine stress echocardiography
J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1311 - 1319.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. l S. Kim, H. Izawa, T. Sobue, H. Ishihara, F. Somura, T. Nishizawa, K. Nagata, M. Iwase, and M. Yokota
Prognostic value of mechanical efficiency in ambulatory patients with idiopathic dilated cardiomyopathy in sinus rhythm
J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1264 - 1268.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. S. Nelson, R. D. Berger, B. J. Fetics, M. Talbot, J. C. Spinelli, J. M. Hare, and D. A. Kass
Left Ventricular or Biventricular Pacing Improves Cardiac Function at Diminished Energy Cost in Patients With Dilated Cardiomyopathy and Left Bundle-Branch Block
Circulation, December 19, 2000; 102(25): 3053 - 3059.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. S. Nelson, C. W. Curry, B. T. Wyman, A. Kramer, J. Declerck, M. Talbot, M. R. Douglas, R. D. Berger, E. R. McVeigh, and D. A. Kass
Predictors of Systolic Augmentation From Left Ventricular Preexcitation in Patients With Dilated Cardiomyopathy and Intraventricular Conduction Delay
Circulation, June 13, 2000; 101(23): 2703 - 2709.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Senzaki, T. Isoda, N. Paolocci, U. Ekelund, J. M. Hare, and D. A. Kass
Improved Mechanoenergetics and Cardiac Rest and Reserve Function of In Vivo Failing Heart by Calcium Sensitizer EMD-57033
Circulation, March 7, 2000; 101(9): 1040 - 1048.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. J. Eichhorn and M. R. Bristow
Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart: A New Era in the Treatment of Heart Failure
Circulation, November 1, 1996; 94(9): 2285 - 2296.
[Abstract] [Full Text]


Home page
NEJMHome page
S. Fazio, D. Sabatini, B. Capaldo, C. Vigorito, A. Giordano, R. Guida, F. Pardo, B. Biondi, and L. Sacca
A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
N. Engl. J. Med., March 28, 1996; 334(13): 809 - 814.
[Abstract] [Full Text] [PDF]